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Leishmaniasis refers to a diverse spectrum of clinical 
syndromes caused by infection with protozoan parasites of 
the genus Leishmania. They are widely distributed across 
the tropical, subtropical, and temperate regions in 88 
countries, 72 of which are in developing areas of the world. 
The diagnosis and treatment of the different syndromes 
produced by these parasites are particularly difficult in 
developed and non-endemic countries because of poor 
knowledge of clinical symptoms, diagnostic possibilities, 
and available treatment options. This article highlights the 
biology, life cycle, diagnostic, chemotherapeutic, and 
strategies to control Leishmaniasis. 
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INTRODUCTION 
 
Leishmaniasis is a neglected vector-borne tropical 
infection that is considered to be a disease of the poor 
(WHO, 2014). It is widely distributed across the tropical, 
subtropical, and temperate regions; extending from china 
across Asia, India, the Arabian Peninsula, the Middle 
East, the Mediterranean basin, East and West Africa and 
South America (Pace,2014). Three hundred fifty million 
women, men, and children are at risk in widely scattered 
areas, with 14 million people directly affected by the 
disease (Pace, 2014). Based on the pattern of organ 
pathology, leishmaniasis is sub-divided into three clinical 
types, namely visceral (kala-azar), the most important 
disease; cutaneous, the most common; and muco-
cutaneous. Among parasitic diseases, mortality from 
leishmaniasis is second only to malaria and, in terms of 
disability-adjusted life years (DALYs), the third-most 
common cause of morbidity after malaria and 
schistosomiasis, with children under 15 years of age 
suffering most of the disease burden (Daniella, 2015). 
The number of cases of visceral   leishmaniasis   (VL)   is 
 
 
 
calculated to be as high as 0.2–0.4 million people per 
year, approximately 90% of all these are found in three 
areas: the drainage basin of the Ganges river in eastern 
India and neighboring areas of southern Nepal (Terai) 
and areas of Bangladesh that share the same ecology; 
the Sudan, where a large epidemic has occurred among 
displaced people (Alvar et al., 2012). 
Cutaneous leishmaniasis (CL) has been considered by 
the World Health Organization (WHO) a category 1 
emerging and uncontrolled disease (De Vries et al., 
2015), approximately 90% of the world’s CL cases occur 
in Iran, Saudi Arabia, and Syria in the Middle East; in 
Afghanistan in Central Asia; and in Brazil and Peru in 
Latin America (Desjeux, 2004). Approximately 35,000 
cases of mucosal leishmaniasis occur annually, mainly in 
Brazil, Peru, and Bolivia (Pace, 2014). VL is hypo 
endemic in Mediterranean countries; cases in this area 
account for 5–6% of the global burden (Daniella, 2015). It 
does not necessarily lead to clinical disease; most 
infections remain   asymptomatic,  but   malnutrition   and  
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immune suppression, notably HIV, predispose to clinical 
diseases (Okwor and Uzonna, 2013). VL has also 
emerged as an important opportunistic disease in 
persons with acquired immunodeficiency syndrome 
(AIDS) in the Mediterranean region, mainly in France, 
Italy, Portugal, and Spain (Monge-Maillo et al., 2014). 
Since highly active antiretroviral therapy was introduced 
in 1997, a marked decrease in the number of co-infected 
cases both in these regions and in India have been 
reported (Singh, 2014). Persons who have had organ 
transplants, and in association with other conditions in 
which cell-mediated immunity is compromised, VL 
presents as opportunistic disease.  In a multicenter study 
by Clemente, it was observed that diagnosis was 
frequently delayed and relapses were common after 
treatment (Clemente et al., 2015). This disease remains a 
major neglected tropical disease, and a strategic 
framework for its control in the WHO European region 
has been applied (World Health Organization, Regional 
Office for Europe, 2014). 
 
 
LIFE CYCLE 
 
These intracellular protozoa have a complex digenetic life 
cycle, requiring a susceptible vertebrate host and a 
permissive insect vector, which allow their transmission. 
Female sand flies of the genus Lutzomyia in the 
Americas and Phlebotomus elsewhere transmit 
Leishmania spp. (Lewis, 1987). The sand flies are 
modified pool feeders, meaning that they feed on pooled 
blood from their bite. Adults, males and females, are 
recognized by their small size, hairy body, the wings held 
erect on the body when resting, and a bouncy flight. 
Females are blood feeders and, in general, tend to bite at 
night or in twilight, but also can sting during the day in 
forested areas (Brazil et al., 2015). 
 
 
MODE OF TRANSMISSION 
 
Bite of an infected sandfly mainly during the late evening 
or the night time. Minimum 10–1,000 promastigotes per 
infective bite are required to initiate the infection (Apurba 
et al., 2014). 
 
 
 
VERTEBRATE HOSTS, INCLUDING HUMANS 
 
Promastigotes are regurgitated from the midgut rarely or 
directly discharged from foregut (proboscis) of the female 
sandfly into the skin of the vertebrate host. Promastigotes 
are phagocytosed by the skin macrophages and 
transform into amastigote forms within 12–24 h. The 
amastigote forms inside the macrophages multiply further  
Direct Res. J. Health Pharm.         28 
 
 
 
causing cell rupture and release into the circulation. 
Amastigotes are carried out in the circulation to various 
organs like liver, spleen and bone marrow and invade the 
reticuloendothelial cells like macrophages and endothelial 
cells (Apurba et al., 2014). 
 
SANDFLY 
 
During the blood meal taken up by the sandfly, the 
amastigotes are ingested and transformed into 
promastigote forms in the insect midgut. Promastigotes 
multiply by longitudinal fission and pass through various 
stagessuch as: 
 
Amastigote → procyclic promastigote → nectomonad 
promastigote → haptomonad promastigote →leptomonad 
promastigote → metacyclic promastigote (Apurba and 
Sandhya, 2014). The metacyclic promastigotes multiply 
in the midgut of vector by binary fission and a small 
proportion migratesto the foregut (proboscis). They infect 
a new host during another blood meal. The duration of 
the life cycle in sandfly varies from 4 to 18 days 
depending on the specie (Apurba and Sandhya, 2014) 
(Figure 1). Depending on the Leishmania sp., the sandfly 
genus, and the geographic location, the major reservoirs 
are canines, rodents, or humans (Andrade et al., 2007; 
Bates, 2007). Although most transmission is by sandfly 
bites, Leishmania can be transmitted by blood 
transfusions, sharing of needles by intravenous drug 
abusers, occupational exposures, congenital 
transmission, and rarely by sexual transmission (Dey and 
Singh, 2006).  Leukodepletion effectively reduces or 
eliminates transfusion-associated risk of Leishmania 
infection (Cruz et al., 2002). 
 
CLASSIFICATION OF LEISHMANIASIS 
 
Leishmania has two subgenera L. Leishmania and L. 
Viannia. The main difference between the twosubgenera 
is that promastigotes of the subgenus Viannia develop in 
the midgut andhindgut of sandfly where as that of 
subgenus Leishmania develop in the anterior portionof 
the alimentary tract of sandfly. Both of the subgenera 
comprise of nearly 20 specie (Abazid et al., 2012); Old 
world leishmaniasis: Affects Asia, Africa and Europe and 
transmitted by sandfly (Genus Phlebotomus) New World 
Leishmaniasis: Affects Central and South America and 
transmitted by sandfly (Genus Lutzomyia) (Tables 1-3). 
 
CLINICAL SYNDROMES OF LEISHMANIASIS 
INCLUDE 
 
Visceral leishmaniasis (VL) 
Post–kala-azar dermal leishmaniasis (PKDL) 
Cutaneous leishmaniasis (CL) 
Diffuse cutaneous leishmaniasis (DCL) 
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Figure 1. Sandfly mode of transmission of leishmaniasis. 
 
 
 
 
 
Leishmaniasis recidivans (LR) 
Mucocutaneous leishmaniasis (MCL) 
 
 
VISCERAL LEISHMANIASIS (VL) 
 
Visceral leishmaniasis is mainly caused by the L. 
donovani and sometimes by L. infantum, (designated as 
L. chagasi in the New World) together known as L. 
donovani complex (Kuhls et al., 2011). VL is a spectrum 
of symptoms and findings. At one extreme are persons 
with asymptomatic, in appearance, or self-resolving 
infections. At the other end are those with classic VL 
(kala-azar), with a characteristic pentad of prolonged 
fever, weight loss, hepatosplenomegaly, pancytopenia, 
and hypergammaglobulinemia. Ratios of asymptomatic  
 
infection to VL cases are reported to range from 6.5: 1 in 
children to 18: 1 in adults with L. infantum/L. chagasi in 
northeastern Brazil (Evans et al., 1992). The incubation 
period for full-blown visceral leishmaniasis is typically 3- 8 
months, Persons who are immunocompromisedby AIDS, 
neoplasm, or immunosuppressive therapy are at 
increased risk of asymptomatic parasitemia (Orsini et al., 
2012) and developing progressive disease. Classic 
visceral leishmaniasis, or kala-azar, is characterized by 
fever, malaise, weight loss, hepatomegaly, and 
splenomegaly.  
The onset of symptoms is usually insidious, but on 
occasion it is abrupt and may suggest malaria or other 
acute infections. The fever may be intermittent, remittent 
with twice daily   temperature  spikes  or  less  commonly,  
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Old world Leishmaniasis 
 
Table 1. Leishmania Leishmania (L. L.) donovani complex 
 
Species Geographical 
distribution 
clinical 
syndrome 
Vector 
(sandfly) 
Reservoir Transmission 
L. L. donovani South Asia (Indian subcontinent) VL (Kala-azar) 
PKDL 
Phlebotomus 
argentipes 
Humans Anthroponotic 
 Sudan, Ethiopia, Kenya and Uganda VL, PKDL P. orientalis, P. 
martini 
Humans/ 
rodents 
Anthroponotic/ 
Zoonotic 
 Middle East, Africa and China VL P. perniciosus   
L. L. infantum Mediterranean, Middle East, Central 
Asia and China 
VL, CL P. perniciosus Dogs, 
foxes, 
jackals 
Zoonotic 
 
Table 2. L. L. tropical complex 
 
L. L. tropica Western India, North Africa, 
Mediterranean, littoral, Middle East 
CL, LR P. sergenti Humans Anthroponotic 
L.L. aethiopica Ethiopia, Uganda, and Kenya CL, DCL P. longipes Hyraxes Zoonotic 
L. L major Middle East, India, China Africa, central and western Asia CL P. papatasi Rodents Zoonotic 
 
 
Table 3. New world Leishmaniasis 
 
L. L. chagasi (new world 
variant of L.L. infantum) 
Central and South America VL, CL Lutzomyia spp. Dogs 
Foxes 
Zoonotic 
L. L. Mexicana Complex Central America and northern parts 
of South America 
CL, 
DCL 
Lutzomyia spp. Forest 
rodents 
Zoonotic 
L. Viannia braziliensis 
Complex 
South and  
Central America 
CL, 
MCL 
Lutzomyia spp. Forest 
rodents 
Zoonotic 
 
Abbreviations: VL, Visceral leishmaniasis; PKDL, post-kala-azar dermal leishmaniasis; CL, cutaneous leishmaniasis; LR, 
leishmaniasis recidivans DCL, diff use cutaneous leishmaniasis; MCL, mucocutaneous leishmaniasis. 
 
 
 
and continuous. On physical examination, the spleen is 
firm, non tender, and frequently massively enlarged. 
 
 
VISCERAL LEISHMANIASIS IN PATIENTS WITH AIDS 
 
Persons with concurrent visceral leishmaniasis and HIV 
infection present in a classic manner with fever, weight 
loss, and organomegaly and pancytopenia when patients 
have CD4+ counts greater than 50 cells/mm3, but atypical 
presentations and localization of parasites are more 
common when CD4 cells are less than 50 
cells/mm3(Rosenthal et al., 2000). AIDS patients have 
extensive gastrointestinal tract involvement that includes 
oral mucosa, esophagus, stomach, and small intestine 
and may present with chronic diarrhea. 
 
 
VISCEROTROPIC LEISHMANIASIS 
 
This is a systemic syndrome characterized by chronic 
low-grade fever, malaise, fatigue, and in some instances, 
diarrhea associated with L. tropica infection seen among 
U.S. military personnel who served in the Persian Gulf 
War of 1990 to 1991(Magill et al., 1994). Leishmania 
were isolated from the bone marrow specimens of these 
troops, who did not develop massive splenomegaly, 
wasting, or the progressive deterioration associated with 
classic kala-azar. 
 
 
Post-kala-azar dermalLeishmaniasis 
 
It is a nonulcerative lesion of skin occurs in 2–50% of 
patients of VL following the completion of treatment. It is 
mainly seen in India and East African countries. PKDL is 
more commonly seen after treatment with pentavalent 
antimony (SbV) compounds and appears to be less 
common after successful treatment with amphotericin B 
formulations (Thakur et al., 2008). The skin lesions of 
PKDL are chronic and may persist for as long as 20 
years in India, whereas in the Sudan, they persist for only 
a few months to a year. The skin lesions vary from hyper 
pigmented  or  hypo  pigmented  macules  progressing  to  
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papules, nodules, and verrucous forms (Sultana et al., 
2012). 
 
 
CUTANEOUS LEISHMANIASIS 
 
The spectrum of disease ranges from single, chronic 
ulcerative lesions (often referred to as "oriental sores") to 
disseminated, nonulcerative nodular lesions (a rare 
syndrome known asdiffuse cutaneousleishmaniasis). 
Cutaneous leishmaniasis (CL) has been endemic in 
Aleppo, Syrian Arab Republic for centuries, giving the 
disease one of its common names, Aleppo boil (Canaan, 
1929). 
New World CL is endemic in widespread areas of Latin 
America. The causative species include L. braziliensis, L. 
Mexicana, L. panamensis andL. Guyanensis. Old World 
cutaneous leishmaniasisin the Mediterranean basin, the 
Middle East, southern Asia, India, and Africa are caused 
by three Leishmania species: L. major, L. tropica, and L. 
aethiopica (Alan, 2015). At the initial bite site, a papule 
forms, enlarges to a papulonodule, usually develops 
central ulceration, and slowly enlarges. Surrounding in 
duration and raised borders are typical (Herwaldt et al., 
1992). CL is characterized by a mixed acute and chronic 
inflammatory infiltrate with infected and non infected 
mononuclear phagocytes, lymphocytes, and plasma 
cells. There are areas of focal necrosis (Hai et al., 2004). 
Leishmaniasis simulate a polar disorder similar to other 
intracellular infections such as leprosy (Alan, 2015; Barral 
et al., 2004), ML, LR LCL DCL. For example, the range of 
clinical features in CL parallels that of leprosy. At the 
polyparasitic end of the spectrum is diffuse cutaneous 
leishmaniasis (DCL), a relatively uncommon syndrome, in 
which there is little evidence of effective cell-mediated 
immune response. Peripheral blood mononuclear cells 
neither proliferate nor produce interferon-γ (IFN-γ) nor 
interleukin-2 (IL-2) in response to leishmanial antigens in 
vitro and cutaneous delayed-type hypersensitivity (DTH) 
reactions are absent (Silveira et al., 2004). DCL has been 
compared with lepromatous leprosy, in which there is a 
large number of mycobacteria in macrophages and no 
evidence of protective, Th1 cell–mediated immune 
responses. At the oligoparasitic end of the spectrum is 
leishmaniasis recidivans (LR), a hyperergic variant of CL 
caused by L. tropica infection in the Old World, in which 
chronic lesions slowly expand while healing at the center. 
Amastigotes are sparse, and a mononuclear cell infiltrate 
predominates. This is somewhat analogous to tuberculoid 
leprosy, in which there is an intense mononuclear 
infiltrate with few mycobacteria. 
Knowledge of immunology of these parasites is 
important to ascertain the clinical spectrum of the 
disease. Oligoparasitic, such as ML and LR, are 
characterized by very few recognizable parasites, an 
exaggerated cell mediated immune response, and a 
minimal antibody response. 
 
 
 
 
A review concerning outbreaks in Israel over a recent 13-
year period revealed an expansion of CL illness in 
southern, central, and northern areas of the country 
(Gandacu et al., 2014). Therefore, studies of the 
responsible factors and a greater degree of public 
alertness are necessary (Daniella, 2015). 
 
 
DIAGNOSIS  
 
The diagnosis of leishmaniasis is frequently delayed and 
may be missed. Clinical diagnosis of VL has a pentad of 
prolonged fever, progressive weight loss, pronounced 
hepatosplenomegaly, pancytopenia and 
hypergammaglobulinemia from a known endemic area 
(Pace, 2014). Several methods of laboratory diagnosis of 
leishmaniasis have been reported (Elmahallawy et al., 
2014), these include parasite detection by microscopic 
examination, culture and successive isoenzyme analysis 
for identification, or molecular biology-based assays for 
detecting the parasite DNA (polymerase chain reaction 
[PCR].  The diagnosis may be difficult in patients with 
late-stage HIV infection or AIDS and returning travelers 
who present with atypical signs and symptoms. The 
confirmation of diagnosis is done by parasitologic 
demonstration of amastigotes in tissue, by isolating 
promastigotes in culture, or with a positive PCR assay 
(Alan, 2015). Splenic aspiration, liver biopsy, lymph node 
aspirates, and bone marrow aspirates have all been used 
with success (Alan, 2015). The spleen is the most 
sensitive location, the sensitivity of a bone marrow 
aspirate approaches that of a splenic aspirate when 
microscopists spend more time reviewing the smear 
(Sarker et al., 2004). Bone marrow aspiration is safer and 
preferred in non-endemic settings but is less sensitive. 
Amastigotes may also be seen within mononuclear cells 
in Wright- and Giemsa stained smears of the buffy coat. 
Aspirates from the spleen, bone marrow, liver, or lymph 
node can be cultured. Specimens can be inoculated into 
media such as Schneider’s modified or Novy-MacNeal-
Nicolle [NNN] and maintained at ambient temperatures 
22-26°C. 
Enzyme-linked immunosorbent assay and dipstick tests 
using L. infantum/L. chagasi recombinant k39 (rk39), a 
kinesin-like antigen (Burns et al., 1993) have 
demonstrated excellent sensitivity and specificity for the 
diagnosis of VL in immuno competent persons in India 
and Brazil but less so in East Africa, (Ritmeijer et al., 
2006; Chappuis et al., 2006; Braz et al., 2002).  
Cutaneous leishmaniasis, a definite diagnosis is made by 
identifying amastigotes in tissue, promastigotesin culture, 
or by amplifying Leishmania-specific DNA or RNA in a 
PCRassay. Specimen can be obtained from an ulcer 
base after meticulous and thorough cleaning and removal 
of exudate before the scraping, aspiration, or biopsy. 
Scrapings are often successful in confirming the 
diagnosis. Culture  and  PCR  assays  are  also  done  for  
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confirmation of the diagnosis (Alan, 2015). The biopsy 
specimen should be divided and used for culture, touch 
preparation, and histopathology. Serologic assays are not 
generally helpful in the diagnosis of CL. a positive 
serological test for leishmanial antibodies provides only 
presumptive evidence of infection because cross-reacting 
antibodies may be present in persons with Chagas' 
disease or leprosy. 
 
 
TREATMENT 
 
Leishmania infections have genetic heterogeneity with 
each region having different species complexes. These 
differences may be reflected in variable natural history of 
infection and response to treatment. Different sandfly 
vectors, mammalian reservoirs, and human hosts with 
different genetic backgrounds could also be responsible 
in variable response to treatment (Alan, 2015). The drugs 
employed to treat VL are expensive and sometimes have 
toxic side effects (Daniella, 2015). Single dose liposomal 
amphotericin B (AmBisome; Astellas, Northbrook, IL) 
leads to greater than 95% efficacy in India (Mueller et al., 
2007) but requires a much higher total dose in the Sudan 
(Mueller et al., 2006; Sundar et al., 2014). 
Paromomycin, an aminoglycoside antibiotic, is used for 
the treatment of both VL and CL in parenteral and topic 
formulations. Open-label study evaluated the efficacy of 
two treatment options, single infusion of preformed 
amphotericin B (AmB) lipid and injectable Paromomycin, 
an aminoglycoside (Sundar et al., 2007).The 
Paromomycin was shown to be non-inferior to 
amphotericin. Miltefosine was registered in India in 2002 
as the first oral antileishmanial agent; it is a 
phosphocholine analogue, its major limitations are the 
high cost, the need for monitoring of gastrointestinal side-
effects, and occasional hepatic and renal toxicity (Sundar 
et al., 2012). Combining Paromomycin with miltefosine, 
the release of nitric oxide and tumor necrosis factor by 
human macrophages was induced, enhancing the killing 
of L. donovani promastigotes in vitro (Das et al., 2012). 
Pentavalent antimony, multiple preparations of this 
drug exist; Sodium stibogluconate (SSG; Pentostam, 
Glaxo Smith-Kline, Brantford, Middlesex, England), and 
meglumine antimoniate (MA; Glucantime, Sanofi-Aventis, 
Paris) are the two best known commercial products. SbV 
is still used for the treatment of VL in areas where 
Leishmania isolates remain susceptible. In many cases 
treatment failure is due to abnormalities in the host's 
immune system or sometimes attributable to drug 
resistance in the parasite, in this situation liposomal 
amphotericin B, amphotericin B deoxycholate, or 
miltefosine can be used. Primary failures and relapses 
are often observed in patients with concurrent AIDS 
(Alan, 2005). For cutaneous lesions especially in 
cutaneous leishmaniasis, several drugs have been used;  
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these include Sodium stibogluconate Amphotericin B and 
pentamidine. Local injections of SbV have been used 
successfully in some settings. Oral systemic treatment in 
Old World CL with several agents has been studied. 
Fluconazole (Alrajhi, 2002) and Itraconazole (Nassiri-
Kashani et al., 2005) all appear to have activity against 
some Leishmania species. In all forms of CL, attention 
should be directed to local wound care. CL is both a 
parasitic infection and an open wound. Antibiotics should 
be administered if there is evidence of cellulitis, painful or 
tender areas, or purulence. 
 
 
PREVENTION 
 
Standard personal protective measures, such as N, N-
diethyl-meta-toluidine (DEET)-based insect repellents 
and permethrin or other insecticides applied to clothing 
and insecticide impregnated fine-mesh bed nets all 
provide protection against sand flies if used correctly 
(Soto et al., 2006). Vector control and reservoir control 
are effective. Although no commercial vaccine is currently 
available, there is a rationale to expect one in the future. 
The spontaneous resolution of human infection is 
associated with high-level immunity against the 
homologous infecting Leishmania spp. Phlebotomus are 
not known to fly high above the ground level and it is 
nocturnal in habitat. So, sleeping at top floors or on the 
beds high above the ground can prevent transmission. 
Early treatment of all cases is of paramount important. 
 
 
CONCLUSION 
 
Leishmaniasis is not only a neglected tropical disease, it 
is also a major health problem worldwide. It produces 
varying group of clinical syndromes ranging from self-
healing cutaneous ulcers (in apparent) to fatal visceral 
disease. It is mainly a zoonotic disease affecting dogs, 
foxes, jackals and rodents. Animal reservoir plays a 
major role for transmission. Lot of risk factors associated 
with Leishmania distribution have been implicated; these 
include, socioeconomic conditions, malnutrition, 
population mobility, and environmental and climate 
changes. Prevention and control are based on early 
diagnosis and treatment, vector control, disease 
surveillance, and education of the community (Daniella, 
2005). It is second protozoan infection of medical 
importance to for human health after malaria, 
Parasitological diagnosis is made on the basis of biopsy 
results, and treatment requires drugs that are toxic and 
expensive. Many of these drugs are still out of reach. 
Spraying of houses with residual insecticide is difficult to 
sustain, as is control of animal reservoirs (e.g., dogs, for 
VL). Recent research has resulted in the development of 
insecticide, treated bed nets, miltefosine, and cheap and  
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reliable serological tests for leishmaniasis (Guerin et al., 
2002; Davies et al., 2003). 
 
 
Dedication 
 
This article is dedicated to Prof. Rasheed Bakare, a 
brilliant Medical Practitioner, teacher and mentor. Bakare 
is well-known as a visiting teacher in different prestigious 
institutions of West African countries and for various 
projects. His special interest in sexually transmitted 
diseases and infectious diseases has earned him respect 
among his colleagues. He has trained quite a number of 
Medical doctors, Nurses and Medical Laboratory 
Scientists both at undergraduate and postgraduate 
levels. I am proud to know him as a mentor, teacher and 
a senior professor in the field of Medical Microbiology and 
Parasitology. 
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